Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about CCEL, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Cord Tissue Mesenchymal Stromal Cells | Autism | Phase 2 · NCT04089579 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
CCEL holds $4.2M in cash and short-term investments (as of Aug 31, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CCEL files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| David Portnoy Chairman, Co-CEO, Director, 10% owner · +679,879 options |
Insider | 1,515,637 | 18.80% | 2026-08-05 |
| Mark L. Portnoy Co-CEO, Director, 10% owner · +267,222 options |
Insider | 935,768 | 11.61% | 2026-01-07 |
| Camac Partners, LLC | 5%+ holder (13D) | 551,081 | 6.83% | 2026-07-02 |
| Oleg Mikulinsky Chief Information Officer · +103,777 options |
Insider | 104,349 | 1.29% | 2026-01-07 |
| Harold D. Berger Director · +55,200 options |
Insider | 57,901 | 0.72% | 2026-10-27 |
| Jill M Taymans VP Finance, CFO · +74,000 options |
Insider | 52,896 | 0.66% | 2026-05-28 |
| Daniel Mizrahi Director · +37,100 options |
Insider | 30,634 | 0.38% | 2026-10-27 |
Share count 8,062,650 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CCEL and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →